Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Cancer Prev Res (Phila). 2022 Apr 1;15(4):225–231. doi: 10.1158/1940-6207.CAPR-21-0227

Figure 2.

Figure 2.

PD-L1 expression is decreased by COX-2 but not COX-1 inhibition. (A) Percent PD-L1 on viable cells on LOVO, RKO or SB10 cells untreated (white bars) or treated with naproxen, 1000 μM (blue bars). (B) Percent PD-L1 on viable cells in MC38 cells untreated (white bar) or treated with naproxen (1000 μM) or celecoxib (100 μM) (blue bars). (C) Percent PD-L1 expression relative to the mock control transfected cells after silencing of the indicated gene in MC38 cells. **p=0.01, ****p<0.0001; n=3-4 independent experiments.